Stock Scorecard



Stock Summary for Rigel Pharmaceuticals (RIGL) - $41.50 as of 8/22/2025 8:34:27 PM EST

Total Score

16 out of 30

Safety Score

57 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for RIGL

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RIGL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RIGL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RIGL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RIGL (57 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 8
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for RIGL

Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU 8/20/2025 4:45:00 PM
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease 8/15/2025 1:50:00 PM
Xeris Biopharma Holdings, Inc. ( XERS ) Hits Fresh High: Is There Still Room to Run? 8/12/2025 1:15:00 PM
Earnings Estimates Moving Higher for Rigel ( RIGL ) : Time to Buy? 8/8/2025 4:20:00 PM
Best Momentum Stock to Buy for August 8th 8/8/2025 2:00:00 PM
5 Best Stocks With Relative Price Strength to Buy Right Now 8/8/2025 1:15:00 PM
New Strong Buy Stocks for August 8th 8/8/2025 10:09:00 AM
Rigel Pharmaceuticals ( RIGL ) Just Flashed Golden Cross Signal: Do You Buy? 8/7/2025 1:55:00 PM
Rigel Pharmaceuticals, Inc. ( RIGL ) Hits Fresh High: Is There Still Room to Run? 8/7/2025 1:15:00 PM
Rigel ( RIGL ) Q2 Revenue Jumps 176% 8/6/2025 11:19:00 AM

Financial Details for RIGL

Company Overview

Ticker RIGL
Company Name Rigel Pharmaceuticals
Country USA
Description Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 41.50
Price 4 Years Ago 26.50
Last Day Price Updated 8/22/2025 8:34:27 PM EST
Last Day Volume 895,230
Average Daily Volume 594,747
52-Week High 41.86
52-Week Low 12.00
Last Price to 52 Week Low 245.83%

Valuation Measures

Trailing PE 7.62
Industry PE 40.56
Sector PE 58.53
5-Year Average PE -73.52
Free Cash Flow Ratio 13.93
Industry Free Cash Flow Ratio 15.42
Sector Free Cash Flow Ratio 30.30
Current Ratio Most Recent Quarter 2.02
Total Cash Per Share 2.98
Book Value Per Share Most Recent Quarter 4.57
Price to Book Ratio 9.05
Industry Price to Book Ratio 29.05
Sector Price to Book Ratio 26.66
Price to Sales Ratio Twelve Trailing Months 2.77
Industry Price to Sales Ratio Twelve Trailing Months 25.49
Sector Price to Sales Ratio Twelve Trailing Months 13.25
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 17,937,300
Market Capitalization 744,397,950
Institutional Ownership 78.36%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 1.33%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 1,787.00%
Annual Earnings Growth 169.69%
Reported EPS 12 Trailing Months 5.43
Reported EPS Past Year 3.91
Reported EPS Prior Year 1.39
Net Income Twelve Trailing Months 97,821,000
Net Income Past Year 17,485,000
Net Income Prior Year -25,091,000
Quarterly Revenue Growth YOY 176.00%
5-Year Revenue Growth 24.77%
Operating Margin Twelve Trailing Months 60.10%

Balance Sheet

Total Cash Most Recent Quarter 53,407,000
Total Cash Past Year 56,746,000
Total Cash Prior Year 32,786,000
Net Cash Position Most Recent Quarter 15,955,000
Net Cash Position Past Year 4,338,000
Long Term Debt Past Year 52,408,000
Long Term Debt Prior Year 52,373,000
Total Debt Most Recent Quarter 37,452,000
Equity to Debt Ratio Past Year 0.06
Equity to Debt Ratio Most Recent Quarter 0.69
Total Stockholder Equity Past Year 3,288,000
Total Stockholder Equity Prior Year -28,644,000
Total Stockholder Equity Most Recent Quarter 81,934,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 65,450,000
Free Cash Flow Per Share Twelve Trailing Months 3.65
Free Cash Flow Past Year 31,435,000
Free Cash Flow Prior Year -20,743,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 5.28
MACD Signal 4.14
20-Day Bollinger Lower Band 8.26
20-Day Bollinger Middle Band 22.06
20-Day Bollinger Upper Band 35.87
Beta 1.21
RSI 88.74
50-Day SMA 19.86
150-Day SMA 14.65
200-Day SMA 16.47

System

Modified 8/21/2025 9:35:14 AM EST